Xuemin Gu

404 total citations
15 papers, 271 citations indexed

About

Xuemin Gu is a scholar working on Cancer Research, Molecular Biology and Statistics and Probability. According to data from OpenAlex, Xuemin Gu has authored 15 papers receiving a total of 271 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Cancer Research, 4 papers in Molecular Biology and 4 papers in Statistics and Probability. Recurrent topics in Xuemin Gu's work include Statistical Methods in Clinical Trials (4 papers), Cancer Genomics and Diagnostics (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Xuemin Gu is often cited by papers focused on Statistical Methods in Clinical Trials (4 papers), Cancer Genomics and Diagnostics (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Xuemin Gu collaborates with scholars based in United States, China and Taiwan. Xuemin Gu's co-authors include J. Jack Lee, Luisa M. Solis, Guosheng Yin, Reuben Lotan, Carmen Behrens, Ignacio I. Wistuba, Humam Kadara, Edward Kim, Diane Liu and Ping Yuan and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Xuemin Gu

15 papers receiving 267 citations

Peers

Countries citing papers authored by Xuemin Gu

Since Specialization

Citations

This map shows the geographic impact of Xuemin Gu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xuemin Gu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xuemin Gu more than expected).

Fields of papers citing papers by Xuemin Gu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xuemin Gu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xuemin Gu. The network helps show where Xuemin Gu may publish in the future.

Co-authorship network of co-authors of Xuemin Gu

This figure shows the co-authorship network connecting the top 25 collaborators of Xuemin Gu. A scholar is included among the top collaborators of Xuemin Gu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xuemin Gu. Xuemin Gu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Montmorillonite-enhanced micro- and nanocomposites for targeted and controlled oral drug delivery systems 2025 ·Applied Clay Science ·(unknown), Xuemin Gu, (unknown), (unknown), (unknown), Peng Jiang, (unknown), (unknown), (unknown), Qi Tao, Dongzhi Hou	3
2	650P Initial results from a phase I/II study of BT7480, a novel nectin-4/CD137 bicycle tumor-targeted immune cell agonist, in patients (pts) with advanced solid tumors 2024 ·Annals of Oncology ·Kyriakos P. Papadopoulos, Afshin Dowlati, Juanita Lopez, Jordi Rodón, Alexander I. Spira, (unknown), Matthew R. Zibelman, (unknown), Amy L. Dickson, (unknown), Xuemin Gu, Herbert T. Cohen, Ming Li, Jürgen Bader, Caroline A. Bray, Sérgio Henrique Sousa Santos, (unknown), Rosina T. Lis, T.R. Jeffry Evans	1
3	A water-soluble drug nanoparticle-loaded in situ gel for enhanced precorneal retention and its transduction mechanism of pharmacodynamic effects 2024 ·International Journal of Pharmaceutics ·(unknown), (unknown), (unknown), (unknown), Xuemin Gu, (unknown), Qinqiang Long, Yongbin Guo, (unknown), (unknown), (unknown), Lin He, Dongzhi Hou	1
4	A novel prognostic biomarker CD3G that correlates with the tumor microenvironment in cervical cancer 2022 ·Frontiers in Oncology ·(unknown), (unknown), Xuemin Gu, Leilei Cao, (unknown), Qi Xiao, Zhijie Wang, Jianjun Wang	7
5	Engineering of Neutrophil Membrane Camouflaging Nanoparticles Realizes Targeted Drug Delivery for Amplified Antitumor Therapy 2021 ·International Journal of Nanomedicine ·(unknown), Xuemin Gu, (unknown), Lei Chu, Mengjiao Xu, Kun Wang, Xiaowen Tong	31
6	Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumour (TGCT): Characterization of hepatic adverse reactions (ARs) 2019 ·Annals of Oncology ·Sebastian Bauer, James H. Lewis, Hans Gelderblom, Michiel A. J. van de Sande, Silvia Stacchiotti, John H. Healey, William D. Tap, Andrew J. Wagner, (unknown), Mihaela Druta, Chien‐Chin Lin, Hideo A. Baba, Antoine Yver, Dale E. Shuster, Jodi L. McGill, Xuemin Gu, Laurie D. DeLeve	4
7	Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC 2018 ·Annals of Oncology ·David Planchard, Pasi A. Jänne, Helena A. Yu, Denis Moro‐Sibilot, Terri Goldberg, Xuemin Gu, (unknown), Jodi L. McGill, Channing Yu, Eric D. Slosberg	1
8	First-in-human study of DS-6051b in patients (pts) with advanced solid tumors (AST) conducted in the US. 2018 ·Journal of Clinical Oncology ·Kyriakos P. Papadopoulos, Leena Gandhi, Pasi A. Jänne, Sai‐Hong Ignatius Ou, Alice T. Shaw, Terri Goldberg, Jonathan Greenberg, Xuemin Gu, Masaya Tachibana, Giorgio Senaldi, Ryota Shiga, Hamim Zahir, Kenji Nakamaru, Erkut Borazanci	15
9	Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development 2014 ·Statistics in Biosciences ·Xuemin Gu, Nan Chen, Caimiao Wei, Suyu Liu, Vassiliki A. Papadimitrakopoulou, Roy S. Herbst, J. Jack Lee	17
10	Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints 2013 ·Contemporary Clinical Trials ·Xuemin Gu, Guosheng Yin, J. Jack Lee	29
11	A Five-Gene and Corresponding Protein Signature for Stage-I Lung Adenocarcinoma Prognosis 2010 ·Clinical Cancer Research ·Humam Kadara, Carmen Behrens, Ping Yuan, Luisa M. Solis, Diane Liu, Xuemin Gu, John D. Minna, J. Jack Lee, Edward Kim, (unknown), Ignacio I. Wistuba, Reuben Lotan	68
12	Reconstructive Strategies for Partial Sacrectomy Defects Based on Surgical Outcomes 2010 ·Plastic & Reconstructive Surgery ·Patrick B. Garvey, Laurence D. Rhines, Lei Feng, Xuemin Gu, Charles E. Butler	31
13	A simulation study for comparing testing statistics in response-adaptive randomization 2010 ·BMC Medical Research Methodology ·Xuemin Gu, J. Jack Lee	12
14	Bayesian adaptive randomization designs for targeted agent development 2010 ·Clinical Trials ·J. Jack Lee, Xuemin Gu, Suyu Liu	2
15	Identification of Gene Signatures and Molecular Markers for Human Lung Cancer Prognosis using an In vitro Lung Carcinogenesis System 2009 ·Cancer Prevention Research ·Humam Kadara, Ludovic Lacroix, Carmen Behrens, Luisa M. Solis, Xuemin Gu, J. Jack Lee, E Tahara, Dafna Lotan, Waun Ki Hong, Ignacio I. Wistuba, Reuben Lotan	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact